Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The first tangible benefits of the deal Dr. Reddy's Labs struck last year with GlaxoSmithKline for supply of over 100 branded formulations have become visible with the Indian company receiving $4 million from its British partner in return for moving dossiers and trademarks for nine currently marketed products in Brazil

You may also be interested in...



Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma

MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India

Will The Next Teva Be From India? Global Scale, Product Mix, And A Strong Balance Sheet Can Trigger Big M&As By Indian Pharma

MUMBAI - News reports of Teva Pharmaceutical Industries Ltd. CEO Shlomo Yanai's recent visit to India sparked rumors that the company may have finally set its sights on the Indian market via a joint venture with Cipla Ltd. But even as the world's largest generic company toys with the idea of entering the sub-continent, leading analysts predict that the next Teva - referencing its multi-fold growth in the last six years - could soon emerge out of India

Novartis And Quark Partner On Phase II siRNA Drug For Kidney Damage Indications

Already partnered in RNA interference with Alnylam, Novartis pays $10 million for an option to Quark's QPI-1002.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel